Emserm, how do you like the following passage transcribed by Seeking alpha from last night's cc ... I find it intriguing, exciting particularly all came out of Dr. Alam, who usually hold back and don't get excited.
..., study 107. Because it is the first promising data in patients who failed treatment with prior pegylated interferon and ribavirin, many of our investigators have said, “perhaps the most exciting clinical results in all of EASL are the interim analysis results from this study”. Study 107 enrolled patients from those who failed the control arms are PROVE 1, PROVE 2, or PROVE 3. These date provide significant insight into the potential opportunity for telaprevir to address this important patient population, and also helped to differentiate telaprevir relative to other protease inhibitors in development. Study 107 is on going and is still enrolling patients. The abstract, that is already online, highlights four-week on treatment data from 32 patients who were in the control arms of the PROVE studies and failed to achieve an SVR and that elected to receive a 12 week triple regiment of telaprevir pegylated interferon and ribavirin followed by an additional12 weeks of pegylated interferon and ribavirin. At the time we submitted the abstract a total of 54 patients had been enrolled in the study. In addition to the data disclosed in the abstract, at EASL we expect to present all available data for more patients who have now reached the four-week time point and we will disclose on treatment data for patients in study 107 who have reached 12 weeks of therapy. These data are early and we do not know yet what percentage will ultimately achieve an SVR result, but the level of response we have seen so far in all patient sub groups make the results very encouraging. A real strength of study 107 is that we are dealing with patients who were enrolled in a prior controlled study and we know their recent treatment history and their response to prior standard of care treatment in exquisite detail. This insight is valuable in clearly defining the potential effect of telaprevir in treating well-defined non-responders, partial-responders, and relapsed patients. I look forward to reviewing the specific results across each of these patient subgroups after the data are disclosed on Thursday.